Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates

Posted by fidest press agency su giovedì, 2 novembre 2017

tumore metastatico1Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune and infectious diseases based on rationally designed consortia of human microbiome-derived bacteria, today announced that it has exclusively sub-licensed key intellectual property from JSR Corporation to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics. These live biotherapeutics have been shown to activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy. The sub-licensed intellectual property is based on the pioneering research of Dr. Kenya Honda, Professor, of Keio University School of Medicine and his collaborators in the University of Tokyo in Japan. An IND filing for the lead product candidate is planned in 2018.“Dr. Honda’s research suggests an entirely new approach to cancer immunotherapy harnessing the human microbiome, which has the potential to significantly enhance the effectiveness of cancer therapies,” said Bernat Olle, PhD, Chief Executive Officer of Vedanta Biosciences. “We are actively developing product candidates containing defined bacterial consortia that activate CD8+ T cells and stimulate the immune system to fight cancer alone and in combination with checkpoint inhibitors. This license to additional intellectual property from Dr. Honda’s institution further strengthens Vedanta’s leading IP position in the microbiome field.” In validated pre-clinical models of cancer, Vedanta’s orally administered product candidates containing defined bacterial consortia induced CD8+ T cells, potentiating the immune system’s attack of tumor cells. The tumor fighting effects of a variety of checkpoint inhibitors were significantly amplified when combined with the bacterial consortia, suggesting a potentially novel approach for combination cancer immunotherapy.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: